194 related articles for article (PubMed ID: 12684606)
1. Feasibility of blood spot PCR in large-scale screening of fragile X syndrome in southern Taiwan.
Chow JC; Chen DJ; Lin CN; Chiu CY; Huang CB; Chiu PC; Lin CH; Lin SJ; Tzeng CC
J Formos Med Assoc; 2003 Jan; 102(1):12-6. PubMed ID: 12684606
[TBL] [Abstract][Full Text] [Related]
2. Pilot fragile X screening in normal population of Taiwan.
Tzeng CC; Cho WC; Kuo PL; Chen RM
Diagn Mol Pathol; 1999 Sep; 8(3):152-6. PubMed ID: 10565687
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of the FMR1 mutation in Taiwan assessed by large-scale screening of newborn boys and analysis of DXS548-FRAXAC1 haplotype.
Tzeng CC; Tsai LP; Hwu WL; Lin SJ; Chao MC; Jong YJ; Chu SY; Chao WC; Lu CL
Am J Med Genet A; 2005 Feb; 133A(1):37-43. PubMed ID: 15637705
[TBL] [Abstract][Full Text] [Related]
4. An effective strategy of using molecular testing to screen mentally retarded individuals for fragile X syndrome.
Tzeng CC; Lin SJ; Chen YJ; Kuo PL; Jong YJ; Tsai LP; Chen RM
Diagn Mol Pathol; 2001 Mar; 10(1):34-40. PubMed ID: 11277393
[TBL] [Abstract][Full Text] [Related]
5. High-throughput analysis of fragile X (CGG)n alleles in the normal and premutation range by PCR amplification and automated capillary electrophoresis.
Larsen LA; Grønskov K; Nørgaard-Pedersen B; Brøndum-Nielsen K; Hasholt L; Vuust J
Hum Genet; 1997 Oct; 100(5-6):564-8. PubMed ID: 9341871
[TBL] [Abstract][Full Text] [Related]
6. A methylation PCR approach for detection of fragile X syndrome.
Panagopoulos I; Lassen C; Kristoffersson U; Aman P
Hum Mutat; 1999; 14(1):71-9. PubMed ID: 10447261
[TBL] [Abstract][Full Text] [Related]
7. Implication of screening for FMR1 and FMR2 gene mutation in individuals with nonspecific mental retardation in Taiwan.
Tzeng CC; Tzeng PY; Sun HS; Chen RM; Lin SJ
Diagn Mol Pathol; 2000 Jun; 9(2):75-80. PubMed ID: 10850542
[TBL] [Abstract][Full Text] [Related]
8. An assessment of screening strategies for fragile X syndrome in the UK.
Pembrey ME; Barnicoat AJ; Carmichael B; Bobrow M; Turner G
Health Technol Assess; 2001; 5(7):1-95. PubMed ID: 11262423
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the human fragile X mental retardation 1 polymerase chain reaction reagents to amplify the FMR1 gene: testing in a clinical diagnostic laboratory.
Nahhas FA; Monroe TJ; Prior TW; Botma PI; Fang J; Snyder PJ; Talbott SL; Feldman GL
Genet Test Mol Biomarkers; 2012 Mar; 16(3):187-92. PubMed ID: 21992462
[TBL] [Abstract][Full Text] [Related]
10. Comparison between the polymerase chain reaction-based screening and the Southern blot methods for identification of fragile X syndrome.
Curtis-Cioffi KM; Rodrigueiro DA; Rodrigues VC; Cicarelli RM; Scarel-Caminaga RM
Genet Test Mol Biomarkers; 2012 Nov; 16(11):1303-8. PubMed ID: 23101592
[TBL] [Abstract][Full Text] [Related]
11. Qualitative assessment of FMR1 (CGG)n triplet repeat status in normal, intermediate, premutation, full mutation, and mosaic carriers in both sexes: implications for fragile X syndrome carrier and newborn screening.
Hantash FM; Goos DG; Tsao D; Quan F; Buller-Burckle A; Peng M; Jarvis M; Sun W; Strom CM
Genet Med; 2010 Mar; 12(3):162-73. PubMed ID: 20168238
[TBL] [Abstract][Full Text] [Related]
12. Simplified strategy for rapid first-line screening of fragile X syndrome: closed-tube triplet-primed PCR and amplicon melt peak analysis.
Rajan-Babu IS; Law HY; Yoon CS; Lee CG; Chong SS
Expert Rev Mol Med; 2015 May; 17():e7. PubMed ID: 25936533
[TBL] [Abstract][Full Text] [Related]
13. A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene.
Wang H; Zhu X; Gui B; Cheung WC; Shi M; Yang Z; Kwok KY; Lim R; Pietilä S; Zhu Y; Choy KW
J Vis Exp; 2019 Sep; (151):. PubMed ID: 31566610
[TBL] [Abstract][Full Text] [Related]
14. Clinical Genetic Testing for Fragile X Syndrome by Polymerase Chain Reaction Amplification and Southern Blot Analyses.
Cai X; Arif M; Wan H; Kornreich R; Edelmann LJ
Methods Mol Biol; 2019; 1942():11-27. PubMed ID: 30900172
[TBL] [Abstract][Full Text] [Related]
15. Simple molecular diagnostic method for fragile X syndrome in Egyptian patients: pilot study.
Meguid NA; Ismail MF; El-Mahdy RS; Barakat MA; El-Awady MK
Acta Biochim Pol; 2014; 61(2):259-63. PubMed ID: 24936518
[TBL] [Abstract][Full Text] [Related]
16. Original article pilot screening for fragile X carrier in pregnant women of southern Taiwan.
Huang KF; Chen WY; Tsai YC; Lin CC; Chen SH; Tseng CY; Tzeng CC
J Chin Med Assoc; 2003 Apr; 66(4):204-9. PubMed ID: 12854871
[TBL] [Abstract][Full Text] [Related]
17. The risk of fragile X premutation expansion is lower in carriers detected by general prenatal screening than in carriers from known fragile X families.
Geva E; Yaron Y; Shomrat R; Ben-Yehuda A; Zabari S; Peretz H; Naiman T; Yeger H; Orr-Urtreger A
Genet Test; 2000; 4(3):289-92. PubMed ID: 11142761
[TBL] [Abstract][Full Text] [Related]
18. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations.
Tassone F; Pan R; Amiri K; Taylor AK; Hagerman PJ
J Mol Diagn; 2008 Jan; 10(1):43-9. PubMed ID: 18165273
[TBL] [Abstract][Full Text] [Related]
19. Methylation analysis of the fragile X syndrome by PCR.
Das S; Kubota T; Song M; Daniel R; Berry-Kravis EM; Prior TW; Popovich B; Rosser L; Arinami T; Ledbetter DH
Genet Test; 1997-1998; 1(3):151-5. PubMed ID: 10464640
[TBL] [Abstract][Full Text] [Related]
20. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel.
Toledano-Alhadef H; Basel-Vanagaite L; Magal N; Davidov B; Ehrlich S; Drasinover V; Taub E; Halpern GJ; Ginott N; Shohat M
Am J Hum Genet; 2001 Aug; 69(2):351-60. PubMed ID: 11443541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
